Zydus Lifesciences gets USFDA’s final approval for Valsartan Tablets

23 Jul 2024 Evaluate

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Valsartan Tablets USP, 40 mg, 80 mg, 160 mg and 320 mg (USRLD: Diovan tablets). Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and paediatric patients one year of age and older. It is also used in adults to treat heart failure (a condition in which the heart is unable to pump enough blood to the rest of the body) and to improve survival after a heart attack.

The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ - II, India. Valsartan tablets had annual sales of $149.5 million in the United States (IQVIA MAT May 2024). The group now has 400 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04. 

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences Share Price

910.00 -4.65 (-0.51%)
01-Jan-2026 10:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1710.85
Dr. Reddys Lab 1253.65
Cipla 1503.15
Zydus Lifesciences 910.00
Lupin 2083.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×